Sana Alajmovic to step down as CEO of Sigrid Therapeutics in early 2026

Stockholm, August 12, 2025 – Sigrid Therapeutics AB (Sigrid) announces that CEO Sana Alajmovic will leave her operational role on January 31, 2026, to take up a new position outside Sigrid’s line of business and which does not compete with the company.

Sana’s decision comes during a period of strong growth for Sigrid, following the launch of Glucose Stabiliser, the completion of SHINE – one of the world’s largest clinical studies in prediabetes – and intensified partnership discussions ahead of an international launch.

“Through her visionary leadership and hard work, Sana has laid the foundation for Sigrid’s next growth phase. The Board is grateful for her contributions and wishes her every success in the next chapter,” says Mattias Ankarberg, Chairman of the Board at Sigrid.

Sigrid Therapeutics was founded in 2014 based on Professor Tore Bengtsson’s research in metabolic health. Tore, currently Chief Scientific Officer and a member of the Board, will remain in his roles and continue to lead the company’s research and product development.

“Leading Sigrid from a research idea to a company with patented technology, clinical evidence, and commercial products has been a fantastic journey. I am extremely proud of the dedicated team driving Sigrid forward,” says Sana Alajmovic.

The Board is now initiating the process to recruit a new CEO.